University of California San Francisco/San Francisco General Hospital
Welcome,         Profile    Billing    Logout  
 5 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hsue, Priscilla
REVERSE-LC, NCT05858515: REVERSE-Long COVID-19 With Baricitinib Study

Withdrawn
3
550
US
Baricitinib 4 MG, Olumiant, Placebo
Vanderbilt University Medical Center, Emory University, University of California, San Francisco, University of Minnesota, Vanderbilt University, Yale University
Post-Acute COVID-19 Syndrome
12/27
12/29
EPIC-HIV, NCT03207945: Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection ( Study)

Recruiting
3
140
US
Alirocumab, Sar236553/REG727, Placebo
University of California, San Francisco, Massachusetts General Hospital
Dyslipidemias, Cardiovascular Diseases, HIV Infections
07/24
07/25
NCT02272946: Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk

Completed
2
43
US
Canakinumab, IL--1β, Placebo
Priscilla Hsue, MD, Massachusetts General Hospital
HIV, Cardiovascular Disease
02/21
12/21
PREVAIL-LC, NCT06161688: Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

Active, not recruiting
2
40
US
Ensitrelvir, ensitrelvir fumaric acid, Placebo
Timothy Henrich, Shionogi Inc.
Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
06/25
12/25
NCT06029712: Heart Failure Polypill at a Safety Net Hospital

Active, not recruiting
2
35
US
Heart failure polypill, Control Rx
University of California, San Francisco, UCSF CAPS-HIV Innovative Grant, UCSF CFAR-ARI HIV Boost Award, ACC/ABC Merck Research Fellowship Award (support for Dr. DeJong)
Heart Failure With Reduced Ejection Fraction, HIV Infections
09/24
12/24
outSMART-LC, NCT05877508: Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Active, not recruiting
2
36
US
AER002, Placebo
Michael Peluso, MD, Aerium Therapeutics, Patient-Led Research Collaborative, PolyBio Research Foundation
Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19
07/24
07/25
CLEAR HIV, NCT05488431: Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial ( Trial)

Recruiting
2
121
US
Bempedoic acid, BA, Placebo
Priscilla Hsue, MD, University of California, Los Angeles, Massachusetts General Hospital
Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis
03/28
03/28
Graf, Jonathan
NAV3-33, NCT05246280: Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Terminated
3
196
US
TC99m-tilmanocept, tilmanocept, Lymphoseek
Navidea Biopharmaceuticals
Rheumatoid Arthritis
07/24
07/24
CONTROL-RA, NCT05306353: CD40L Antagonism in Rheumatoid Arthritis (RA)

Active, not recruiting
2
104
NA
Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN)
Rheumatoid Arthritis
08/25
03/26
NCT06153095: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Recruiting
1/2
30
US, RoW
IMPT-514
ImmPACT Bio
Systemic Lupus Erythematosus, Lupus Nephritis
02/27
02/27
Imboden, John B
No trials found

Download Options